Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

BACKGROUND: Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs. The development of new efficient regimens with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Myungsun, Mok, Jeongha, Kim, Deog Kyeom, Shim, Tae Sun, Koh, Won-Jung, Jeon, Doosoo, Lee, Taehoon, Lee, Seung Heon, Kim, Ju Sang, Park, Jae Seuk, Lee, Ji Yeon, Kim, Song Yee, Lee, Jae Ho, Jo, Kyung-Wook, Jhun, Byung Woo, Kang, Young Ae, Ahn, Joong Hyun, Kim, Chang-Ki, Shin, Soyoun, Song, Taeksun, Shin, Sung Jae, Kim, Young Ran, Ahn, Heejung, Hahn, Seokyung, Won, Ho Jeong, Jang, Ji Yeon, Cho, Sang Nae, Yim, Jae-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335682/
https://www.ncbi.nlm.nih.gov/pubmed/30651149
http://dx.doi.org/10.1186/s13063-018-3053-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335682/
https://www.ncbi.nlm.nih.gov/pubmed/30651149
http://dx.doi.org/10.1186/s13063-018-3053-1

Ejemplares similares